#Encorafenib Market Scope

[priteshwemarketresearch]

Encorafenib Market Share, Size, Analysis, Growth, Industry Statistics and Forecast 2034

Encorafenib Market Overview:

The Encorafenib Market is predicted to develop at a compound annual growth rate (CAGR) of xx% from 2024 to 2034, when it is projected to reach USD xx Million, based on an average growth pattern. The market is estimated to reach a value of USD xx Million in 2024. Kinase BRAF aids in the regulation of signaling and cell proliferation. Melanoma and colorectal cancer are two cancer types that may have it in a mutant (changed) form. Cancer cells can be stopped from proliferating in part by blocking mutant BRAF kinase proteins. Cancer is treated with a few BRAF kinase inhibitors. Market expansion is anticipated over the projected period as a result of product approvals by regulatory agencies in numerous global locations.

Obtain a Copy of This Report Sample:https://wemarketresearch.com/reports/request-free-sample-pdf/encorafenib-market/1496

Companies Covered: Encorafenib Market:

Array BioPharma Inc,

Pfizer,

Pierre Fabre Group

These companies have the potential to drive market growth through various strategies. They can focus on offering innovative and high-performance products, taking advantage of advancements in technology. Additionally, expanding their distribution channels to target new customers would be beneficial. Strategic partnerships and collaborations can also be pursued to strengthen market presence and enhance competitiveness.

Global Encorafenib Market Segmentation

By Type of Formulation Analysis:

By Type of Formulation, the Encorafenib Market is Categories into Tablets, Capsules. The Capsules segment accounts for the largest share of around 87% in 2024.

Encorafenib Market Regional Insights:

North America Market Forecast:

 North America dominate the Encorafenib Market with the highest revenue generating market with share of more than 45%. Advanced healthcare infrastructure and high melanoma prevalence fuel Encorafenib uptake, which is aided by advantageous reimbursement rules that improve patient access and treatment cost, while fierce competition among pharmaceutical massive businesses boosts market dynamics and innovation.

Global Encorafenib Market Dynamics:

A Range of Dynamic Factors, Such as Changing Raw Material Prices, Regulatory Policies, and Technological Developments, Define the Encorafenib Industry. Sociocultural factors that alter consumer tastes and habits, as well as competitive actions by enterprises including price tactics, marketing campaigns, and product development, are equally important in determining market dynamics. For organizations to adapt and prosper in a constantly changing market environment, it is imperative that they comprehend these variables.

Encorafenib Market Trends:

The A market's or sector's overall movement over time, influenced by a variety of factors and predictive of future possibilities, is referred to as a trend. Technology developments, changes in consumer behavior, and macroeconomic upheavals are just a few of the variables that may be causing these trends. A tendency toward increased efficiency and innovation, for example, is shown in the growing integration of automation and artificial intelligence in several businesses. Consumers and businesses alike are selecting ecologically friendly behaviors and products, demonstrating the prevalence of sustainability and eco-consciousness.

Encorafenib Market Challenges:

Encorafenib The term "market challenges" describes the impediments and demands that companies encounter in the marketplace, which may impede their ability to expand and run their operations effectively. Among these difficulties is fierce rivalry, which compels businesses to constantly develop and enhance their products in order to hold onto market share. Recessions and inflation are two examples of economic volatility that can weaken consumer purchasing power and jeopardize financial stability. Businesses may incur additional expenses and complications as a result of regulatory changes and compliance requirements, especially in highly regulated industries.

Key objectives of this research are:

To explore Global Encorafenib Market size by respective indicators.

To scrutinize the sum and estimation of the Global Encorafenib Market, Based on key aspects.

To offer an account of the competitive landscape and investigate their development plans.

To examine the Global Encorafenib Market for growth possibilities, and strategic growth.

To review the Global Encorafenib Market size (volume and worth) from the organization, key market regions, items and applications, and statistical data.

To generate competitive learnings and factors analysis, SWOT examination, and business improvement plans for the future.

To scrutinize the range of available and novel organic business growth strategies.

Directly Purchase a Copy of this Encorafenib Market research report at:https://wemarketresearch.com/purchase/encorafenib-market/1496?license=single

The research includes historical data from 2016 to 2022 and forecasts until 2034, making the report valuable to industry executives, marketing, sales and product managers, consultants, analysts, and stakeholders in clearly presented tables Together, we are looking for documents that are easily accessible graph.

About We Market Research:

WE MARKET RESEARCH is an established market analytics and research firm with a domain experience sprawling across different industries. We have been working on multi-county market studies right from our inception. Over the time, from our existence, we have gained laurels for our deep rooted market studies and insightful analysis of different markets.

Contact Us: https://wemarketresearch.com/

[hello-delveinsight]

Multiple Myeloma Market Size Forecast, Epidemiology Analysis, Emerging Drug Uptake and Key Companies Assessment by DelveInsight

(LAS VEGAS, US) The Multiple Myeloma Market size across the 8MM  i.e. the United States, Eu5(the UK, Germany, France, Italy, Spain), China and Japan, was $16.27bn in 2019 and is increasing with a modest CAGR during the study period (2017-2030), according to DelveInsight, a leading company in healthcare analytics and consulting.  

The market size for Multiple Myeloma therapies will increase dramatically by 2030 due to the arrival of upcoming therapies that will carve out niche roles in the drug landscape. DelveInsight's latest report on Multiple Myeloma Epidemiology and Market indicates that the impressive growth in market size is due to the rise in incident cases of Multiple Myeloma in 8MM, incorporation of immune-therapies in treatment landscape increased patient adherence and adoption of newer therapies. Also, rich emerging pipeline, better diagnosis, rising awareness and expected increase in investment in the R&D activities are some additional factors that are going to fuel the market.

Some key highlights from the report:

The     total incident cases of Multiple Myeloma are expected to reach 91,520 in     2020 in the 8MM

Higher     usage of bortezomib based regimen observed across the US, EU5 and JP;     Bortezomib + Lenalidomide + dex regimen is the preferred treatment choice     in the US and Japan in the first-line compared to Bortezomib +     Melphalan ± Prednisone and Bortezomib + dex regimen in EU5. In the case     of China, higher usage of thalidomide based regimen found in the     first-line setting

Among     emerging therapies, Bristol Myers Squibb and Bluebird Bio's anti-BCMA CAR     T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) is expected to     result in significant revenues owing to promising results, one-time dosing     and premium pricing in heavily pretreated patients

Key     Companies fuelling the Multiple Myeloma market size growth are     GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Roche, Janssen Research     & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda, Amgen,     AstraZeneca etc.

Patent     expiry of multiple blockbuster drugs like Revlimid, Pomalyst, Darzalex and     Kyprolis is on the lines to expire from 2026 onwards, and this will erode     the sales value significantly and the market is expected to decline from     2028 onwards due to cumulative impacts of patent expiry.

Download Multiple Myeloma Sample: https://www.delveinsight.com/sample-request/multiple-myeloma-market

Though Multiple Myeloma is not common cancer; still, it is the second most diagnosed blood cancer in the United States. It is worth highlighting that it is a heterogeneous haematological malignancy in which epidemiology plays an increasingly important role. Over the past years, intensive clinical and molecular epidemiological research has extended the information about its pathogenesis, risk factors, and prognostic components which aided the approval of new drugs. Despite arduous research endeavors, the etiology remains enigmatic. The untimely or prolonged diagnosis has a severe impact on the clinical course of Multiple myeloma and a negative impact on disease-free survival. It's an unfortunate fact that approximately 95% of all the Multiple Myeloma cases are diagnosed at distant stages. The report reviews the changing epidemiology and provides the forecasts upto 2030, highlights treatment patterns, and the health disparity observed in important subgroups of Multiple Myeloma.

Multiple myeloma report contains epidemiological analysis segmented as the following: 

Total     Multiple Myeloma Incident Cases 

Total     Multiple Myeloma Incident cases by Age Distribution

Total     Symptomatic Multiple Myeloma Cases 

Cases     of Multiple Myeloma by Treatment Line 

Gender-specific     cases of Multiple Myeloma

Multiple Myeloma Market Scenario

The current standard of care of Multiple myeloma treatment includes stem cell transplant, conventional chemotherapy, targeted therapy, surgery, and radiation therapy. Chemotherapies can be given alone or in conjunction with other drugs including corticosteroids, proteasome inhibitors, immune-modulators, and monoclonal antibodies, anti-resorptive agents such as bisphosphonates and NSAIDs, or narcotics.  Currently, Lenalidomide is the market leader in multiple myeloma treatment landscape, and usage as monotherapy and also in combination with other therapies can be found across all the settings. Darzalex is also being used by the healthcare experts in combination as doublet, triplet, and quadruplet with existing therapies for the good treatment strategies and better result outcomes and has impacted the MM treatment landscape significantly. Label expansion along with higher usage of Darzalex has translated into higher revenues and expected to generate maximum revenue by 2025 before the competition and expected patent expiry would erode the sales value. At present, among the IMid's agents, Revlimid dominates the Multiple Myeloma market in the 8MM, where it is included in all lines of Multiple Myeloma therapy either as monotherapy or in combination with other drugs. In 2017, Revlimid generated a revenue of USD 7,140 million in the 8MM. Despite the loss of patent exclusivity among the major markets and approval of other potential pipeline candidates, it will continue to maintain a strong presence during the forecast period as a molecule. The novel emerging therapies are expected to bring a paradigm shift in the Multiple Myeloma treatment landscape by catering to larger unmet needs.

 Report includes exhaustive analysis of Multiple Myeloma Pipeline Therapies

Idecabtagene     vicleucel (ide-cel): Bristol Myers Squibb and bluebird bio

Venetoclax     (Venclexta, Venclyxto): AbbVie

JNJ-68284528     LCAR-B38M/JNJ-4528): Janssen Research and Development

Keytruda     (pembrolizumab): Novartis

Melflufen     (melphalan flufenamide): Oncopeptides

Cetrelimab     (JNJ-63723283): Janssen Research and Development

REGN5458:     Regeneron Pharmaceuticals

Iberdomide:     Celgene

NY-ESO-1     C259 T Cells: GlaxoSmithKline

Braftovi     (encorafenib): Pfizer

JCARH125:     Celgene Corporation

Felzartamab     (MOR202): I-Mab Biopharma

Chidamide     (Epidaza): Shenzhen Chipscreen Bioscience

The past couple of decades have shown vast changes in the treatment landscape of Multiple Myeloma, starting with the use of stem cells trailed by the availability of novel treatments such as immunomodulators and proteasome inhibitors that have transformed the natural history of the indication, leading to increased survival times. Ongoing advancements in  emerging Novel therapies such as CAR-T cell and monoclonal antibodies are showing promising results in treating multiple myeloma patients and are also expected to drive the growth of the market. Recent years have witnessed an influx of several pharma companies exploring the Multiple Myeloma market through novel targets and therapies. Although the emerging pipeline candidates will reduce the gaps however, the opportunities will still remain. As a ray of hope, the launch of new drugs have extended the median overall survival of Multiple Myeloma patients to 4-6 years; however the stark reality is that the ten year survival rate is 3%. The long term burden of the therapies makes life pretty difficult for the patients. There is a dire need for a permanent cure. Another hurdle is the existing expensive treatment options that create a barrier for the aged uninsured population to get hold of costly therapies. The factors like drug-induced toxicities, differences in clinical care, access to the therapies in real-world settings are the observed gaps between trial-based and real-world outcomes. DelveInsight believes that the Multiple Myeloma market is an attractive prospect for the companies due to the high unmet needs and low regulatory hurdles. 

Key Trends of Multiple Myeloma Market Report: https://www.delveinsight.com/report-store/multiple-myeloma-market

Scope of the Report

Geography     Covered: 8MM - The United States, EU5 (Germany, France, Italy, Spain,     and the United Kingdom), Japan, and Chine.

Study     Period: 3-year historical and 11-year forecasted analysis (2017-2030).

Markets     Segmentation: By Geographies, By Therapies (Forecasted + Historical).

Companies     Covered: GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Roche, Janssen     Research & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda,     Amgen, AstraZeneca, and several others.

Analysis:     Comparative and conjoint analysis of emerging therapies, Attribute     Analysis,

Case     Studies

KOL's     Views

Analyst's     View

The Multiple Myeloma Marketed drugs covered report are:

Sarclisa     (Isatuximab): Sanofi

Darzalex     (Daratumumab): Janssen Research and Development

Empliciti     (Elotuzumab): Bristol-Myers Squibb and AbbVie

Velcade     (bortezomib): Takeda

Pomalyst     (Pomalidomide): Celgene Corporation

Revlimid     (Lenalidomide): Celgene Corporation

Farydak     (panobinostat): Novartis Pharmaceuticals

Kyprolis     (Carfilzomib): Amgen

Ninlaro     (ixazomib): Takeda Pharmaceuticals

Blenrep     (Belantamab Mafodotin): GlaxoSmithKline

Table of Contents

1

Key Insights

2

Executive Summary of Multiple Myeloma

3

KOL Views

4

SWOT Analysis of Multiple Myeloma 

5

Multiple Myeloma Market Overview at a Glance

6

Disease Background and Overview: Multiple Myeloma 

7

Diagnosis of Multiple Myeloma

8

Multiple Myeloma Epidemiology and Patient Population

9

The United States Multiple Myeloma Epidemiology

10

EU-5 Multiple Myeloma Epidemiology

11

Japan Multiple Myeloma Epidemiology

12

China Multiple Myeloma Epidemiology

13

Multiple Myeloma Treatment

14

Unmet Needs in the Multiple Myeloma Market

15

Patient Journey of Multiple Myeloma

16

Key Endpoints of Multiple Myeloma Clinical Trials

17

Multiple Myeloma Marketed Therapies

18

Multiple Myeloma Emerging Therapies

19

Multiple Myeloma 8 Major Market Analysis

20

8MM Multiple Myeloma Market Size

21

The United States Multiple Myeloma Market Size

22

EU-5 Multiple Myeloma Market Size

23

Japan Multiple Myeloma Market Size

24

China Multiple Myeloma Market Size

25

Market Access and Reimbursement of Multiple Myeloma (MM)  Therapies

26

Multiple Myeloma Market Drivers

27

Multiple Myeloma Market Barriers

28

Appendix

29

DelveInsight Capabilities

30

Disclaimer

31

About DelveInsight

Request a WebEx Walkthrough of the Report: https://www.delveinsight.com/report-store/multiple-myeloma-market

Related Report:

CAR T-Cell Therapy for Multiple Myeloma-Market Insights and Market Forecast-2030 : This report delivers an in-depth understanding of the CAR T-Cell Therapy use for Multiple Myeloma as well as the CAR T-Cell Therapy market trends for Multiple Myeloma. It provides current treatment practices, emerging drugs, CAR T-Cell Therapy market share of the various CAR T-Cell Therapies for Multiple Myeloma, the individual therapies, current and forecasted Multiple Myeloma CAR T-Cell Therapy market Size from 2017 to 2030.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us: Shruti Thakur  info@delveinsight.com  +1(919)321-6187  www.delveinsight.com 

SOURCE DelveInsight Business Research, LLP

[daisyri-me]

Colorectal Cancer Therapeutics Asia-Pacific Market Is Expected To Reach $7.9 Bn By 2023 : Radiant Insights,Inc

Colorectal Cancer (CRC) is the most common cancer and the leading cause of cancer-related mortality globally. There were more than 1.4 million newly diagnosed CRC cases in 2012, accounting for 9.7% of the total number of cancer cases. This figure has been gradually rising in the Asia-Pacific region, with the growing elderly population and increasingly Westernized lifestyles.

Access Full Report With TOC @ http://www.radiantinsights.com/research/colorectal-cancer-therapeutics-in-asia-pacific-markets-to-2023

CRC is a leading cause of death worldwide, accounting for 0.77 million deaths in 2015. Over half of the incident cases of CRC are diagnosed in patients over the age of 50, and as the aged population is projected to grow, the prevalence of CRC is anticipated to increase, acting as a driver for revenue growth.

The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The CRC market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on the presence of various molecular aberrations.

The marketed products landscape comprises a wide range of treatment options, including EGFR-targeted therapies, angiogenesis inhibitors, multiple kinase inhibitors and new chemotherapies. In the current market, RAS-wild-type and RAS-mutant patients can be treated with angiogenesis inhibitors such as Avastin, Cyramza and Zaltrap, while patients with RAS- or KRAS-wild-type mutations can be prescribed EGFR-targeted therapies such as Erbitux and Vectibix. However, significant unmet need remains for products that can treat BRAF-mutant CRC patients. A therapy that targets mutant BRAF - encorafenib plus binimetinib - is being developed in the pipeline.

Request A Sample Copy Of This Report at: http://www.radiantinsights.com/research/colorectal-cancer-therapeutics-in-asia-pacific-markets-to-2023/request-sample

Scope

The CRC Asia-Pacific market will be valued at $7.9 billion in 2023, growing from $4.7 billion in 2016 at a CAGR of 7.9%.

How will immune checkpoint inhibitors such as Keytruda and Tecentriq contribute to growth?

What effect will patent expirations of currently branded therapies have on market value?

The CRC pipeline is large and diverse, with an strong presence of mAbs and targeted therapies.

What are the common targets and mechanisms of action of pipeline therapies?

Will the pipeline address unmet needs such as the lack of targeted therapies available for BRAF-mutant CRC patients?

What implications will the increased focus on targeted therapies have on the future of CRC treatment?

Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.

How have the late-stage therapies performed in clinical trials?

How would the approval of encorafenib plus binimetinib to treat BRAF-mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?

The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.

How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?

How could changes in risk factors such as population age, obesity and lifestyle influence the market?

Licensing deals are the most common form of strategic alliance in CRC, with total deal values ranging from under $10m to over $3 billion.

How do deal frequency and value compare between target families and molecule types?

What were the terms and conditions of key licensing deals?

See More Reports of This Category by Radiant Insights: http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare

Reasons to buy

Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.

Visualize the composition of the CRC market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.

Analyze the CRC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.

Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.

Predict CRC market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.

Identify commercial opportunities in the CRC deals landscape by analyzing trends in licensing and co-development deals.

About Radiant Insights,Inc

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Media Contact: Michelle Thoras 201 Spear Street 1100, Suite 3036, San Francisco, CA 94105, United States Tel: 1-415-349-0054 Toll Free: 1-888-928-9744 Mail: sales@radiantinsights.com